CLOV · Clover Health Investments, Corp. /De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $2.03B | $3.48B | $672.89M | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | $257.33M | $22.73M | ($79.18M) | - |
| R&D | - | - | - | - | - | - |
| SG&A | $214.27M | $176.48M | $187.57M | $207.92M | $120.83M | - |
| Total Operating Expenses | $2.01B | $1.42B | $2.24B | $3.85B | $765.60M | - |
| D&A | $1.69M | $1.33M | $2.51M | $1.19M | $555.0K | - |
| Operating Income | ($85.53M) | ($45.75M) | ($208.54M) | ($370.92M) | ($183.20M) | ($6.86M) |
| Interest Expense | $0 | $0 | $7.0K | $1.33M | $35.99M | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | ($85.55M) | ($43.01M) | ($213.36M) | ($338.84M) | ($587.76M) | ($6.74M) |
| EPS - Basic | - | - | ($0.44) | ($0.71) | ($1.54) | - |
| EPS - Diluted | - | - | ($0.44) | ($0.71) | ($1.54) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.30M | $194.54M | $122.86M | $103.79M | $299.97M | $28.00M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $307.86M | $343.12M | $427.97M | $625.00M | $752.55M | $28.30M |
| Total Assets | $541.01M | $580.74M | $570.67M | $808.62M | $950.80M | $856.42M |
| Current Liabilities | $208.82M | $213.52M | $261.12M | $440.66M | $372.62M | $33.93M |
| Long-term Debt | - | - | - | $0 | $19.94M | - |
| Total Liabilities | $232.31M | $239.60M | $284.28M | $460.88M | $411.49M | $62.91M |
| Stockholders' Equity | $308.70M | $341.14M | $286.39M | $347.74M | $535.41M | $5.00M |
| Retained Earnings | ($2.29B) | ($2.20B) | ($2.16B) | ($1.96B) | ($1.62B) | ($6.76M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($66.93M) | $34.84M | ($115.87M) | ($203.93M) | ($282.33M) | ($2.23M) |
| Investing Cash Flow | $4.08M | $565.0K | $140.01M | $95.13M | ($181.91M) | ($828.00M) |
| Financing Cash Flow | ($53.38M) | ($17.36M) | ($33.86M) | ($4.96M) | $333.98M | $858.23M |
| CapEx | $2.04M | $1.56M | $584.0K | $4.47M | $693.0K | - |
| Free Cash Flow | ($68.98M) | $33.29M | ($116.45M) | ($208.39M) | ($283.02M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 12.7% | 0.7% | -11.8% | - |
| Operating margin | -4.4% | -3.3% | -10.3% | -10.7% | -27.2% | - |
| EBITDA margin | -4.4% | -3.2% | -10.1% | -10.6% | -27.1% | - |
| Net margin | -4.4% | -3.1% | -10.5% | -9.7% | -87.3% | - |
| Free cash flow margin | -3.6% | 2.4% | -5.7% | -6.0% | -42.1% | - |
| FCF / Net income | 0.81 | -0.77 | 0.55 | 0.62 | 0.48 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 11.1% | 12.9% | 9.2% | 6.0% | 18.0% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -15.8% | -7.4% | -37.4% | -41.9% | -61.8% | -0.8% |
| Return on equity | -27.7% | -12.6% | -74.5% | -97.4% | -109.8% | -134.9% |
| Return on invested capital | - | - | - | -84.3% | -26.1% | - |
| Liquidity | ||||||
| Current ratio | 1.47 | 1.61 | 1.64 | 1.42 | 2.02 | 0.83 |
| Quick ratio | 1.47 | 1.61 | 1.64 | 1.42 | 2.02 | 0.83 |
| Cash ratio | 0.37 | 0.91 | 0.47 | 0.24 | 0.81 | 0.83 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | 0.04 | - |
| Debt / Assets | - | - | - | 0.00 | 0.02 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -29791.7x | -278.3x | -5.1x | - |
| Equity multiplier | 1.75 | 1.70 | 1.99 | 2.33 | 1.78 | 171.28 |
| Liabilities / Assets | 0.43 | 0.41 | 0.50 | 0.57 | 0.43 | 0.07 |
| Efficiency | ||||||
| Asset turnover | 3.56 | 2.36 | 3.56 | 4.30 | 0.71 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.9x | 4.5x | 1.6x | 1.3x | 0.6x | - |
| P / S | 0.6x | 1.1x | 0.2x | 0.1x | 0.5x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 40.3% | -32.6% | -41.5% | 416.7% | - | - |
| Revenue CAGR (3y) | -17.9% | 26.8% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | 1031.9% | - | - | - |
| Operating income growth (YoY) | -87.0% | 78.1% | 43.8% | -102.5% | -2569.7% | - |
| Net income growth (YoY) | -98.9% | 79.8% | 37.0% | 42.3% | -8614.2% | - |
| EPS growth (YoY) | - | - | 38.0% | 53.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 44.1% | 26.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -9.5% | 19.1% | -17.6% | -35.1% | 10608.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$49.81M totalInsurance Segment$49.81M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.17
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Hospital & Medical Service Plans
Comparing CLOVER HEALTH INVESTMENTS against the 5 most active filers in the same SIC group.